[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-controls\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-controls":72},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,31,0,25,[9,61,91,115,144,176,201,230,271,303,330,357,382,405,424,448,473,498,520,547,570,602,621,644,677],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100634955","effects-of-exogenous-ketones-on-cognitive-function-in-older-adults-with-prediabetes-100634955",false,"NCT07546409","Effects of Exogenous Ketones on Cognitive Function in Older Adults With Prediabetes?","Can Exogenous Ketone Supplementation Compensate for Glucose Hypometabolism and Improve Cognitive Processing Speed in Veterans With Prediabetes?","Inclusion Criteria:\n\n* Age 60 to 75 years\n* Able to provide written informed consent\n* Fluent in English\n* No diagnosed cognitive impairment or dementia\n\nClassified as either:\n\n* Prediabetes (based on American Diabetes Association criteria), or Normal glucose regulation (control group)\n* Medically stable and cleared to undergo positron emission tomography and magnetic resonance imaging\n* Willing to comply with study procedures, including metabolic testing, supplement ingestion, and neuroimaging\n\nExclusion Criteria:\n\n* Diagnosis of mild cognitive impairment, dementia, or other neurodegenerative disorder\n* Diagnosis of type 1 diabetes or type 2 diabetes\n* Use of glucose-lowering medications (e.g., insulin, metformin, glucagon-like peptide-1 receptor agonists)\n* History of major neurological disorder (e.g., stroke, traumatic brain injury with loss of consciousness \\>30 minutes, epilepsy, multiple sclerosis)\n* Major psychiatric disorder not stable on treatment\n* Uncontrolled hypertension or significant cardiovascular disease\n* Severe renal, hepatic, or gastrointestinal disease that may affect supplement metabolism\n* Contraindications to magnetic resonance imaging (e.g., non-compatible implanted devices, severe claustrophobia)",true,"ALL","60 Years","75 Years",{"count":22,"type":23},20,"ESTIMATED","INTERVENTIONAL",[26],"NA","Brief Summary\n\nThe goal of this clinical trial is to learn whether older adults with prediabetes, but no diagnosed cognitive impairment, show early changes in brain energy use and thinking speed compared to older adults with normal blood sugar levels. The study will also test whether a single dose of an exogenous ketone supplement can improve brain energy use and cognitive processing speed.\n\nThe main questions it aims to answer are:\n\nDo older adults with prediabetes have lower brain glucose uptake and slower cognitive processing speed compared to those with normal glucose levels?\n\nDoes a single dose of an exogenous ketone monoester supplement improve cognitive processing speed and brain glucose uptake?\n\nResearchers will compare older adults with prediabetes to older adults with normal glucose levels to determine whether differences exist in brain glucose metabolism and cognitive performance. In a subset of participants, researchers will also compare brain and cognitive outcomes before and after consuming a ketone monoester supplement (DeltaG, Oxford, England).\n\nParticipants will:\n\nComplete metabolic testing to determine glucose status\n\nUndergo brain imaging using fluorodeoxyglucose positron emission tomography combined with magnetic resonance imaging (18FDG-PET\u002FMRI) while performing a cognitive processing speed task\n\nConsume a single dose of a commercially available ketone monoester supplement during one study visit\n\nComplete cognitive testing during imaging to measure processing speed and brain activity\n\nThe results of this study will help determine whether early metabolic dysfunction is linked to reduced brain energy use and whether ketones can temporarily support brain function in individuals at risk for dementia.",[29,30],"Prediabetes","Healthy (Controls)",[32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47],"Prediabetic State","Insulin Resistance","Brain Glucose Metabolism","Cerebral Glucose Uptake","Fluorodeoxyglucose F18","Positron-Emission Tomography","Magnetic Resonance Imaging","Functional Magnetic Resonance Imaging","Cognitive Dysfunction","Dementia","Aging","Processing Speed","Ketone Bodies","beta-Hydroxybutyrate","Neuroimaging","Brain Energy Metabolism","RECRUITING","2026-06-30",{"date":51,"type":52},"2026-07-02","ACTUAL",{"date":54,"type":52},"2025-05-20",{"date":56,"type":23},"2027-05-31",{"name":58,"class":59},"University of Alabama at Birmingham","OTHER",2,{"id":62,"slug":63,"hasResults":12,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":70,"conditions":71,"keywords":76,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":90},"100489688","a-repository-to-study-host-microbiome-interactions-in-health-and-disease-100489688","NCT05656378","A Repository to Study Host-Microbiome Interactions in Health and Disease","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Aged \\>0 years. Only participants \\>3 years old will be seen at the NIH CC.\n* Willing to allow biological samples and data to be stored for future research.\n* Willing to provide at least one of the requested biospecimens.\n\nEXCLUSION CRITERIA:\n\n* An individual who has any condition that, in the judgment of the investigator, may put them at undue risk or make them unsuitable for participation in the study will be excluded.\n* For additional gastrointestinal and skin biopsies only, individuals on blood thinners unless they have already been stopped for the procedure.\n* For additional gastrointestinal biopsies only, individuals who have a history of gastrointestinal perforation with endoscopic biopsies will be excluded from the collection of additional gastrointestinal biopsies for the repository.\n* For additional gastrointestinal biopsies only, healthy children (\\\u003C18 years old).\n* For skin biopsies only, individuals who have a history of keloid formation.\n* For vaginal swabs and vaginal fluid only, individuals who have not started menses.\n* For breast milk only, non-lactating individuals.",{"count":68,"type":23},600,"OBSERVATIONAL","Background:\n\nThe microbiome is the bacteria and other microorganisms that live inside and on the body. The microbiome is important for our health. Researchers study how the microbiome help people stay healthy. They study how the microbiome affects the body when people get sick. To do this research, they need samples of the microbiome living on the bodies of many people. The purpose of this natural history study is to collect microbiome samples in a repository. These samples will be used for future research.\n\nObjective:\n\nTo collect microbiome samples from the body that can be used for future research.\n\nEligibility:\n\nPeople of any age. Only those older than 3 years will be seen at the NIH clinic.\n\nDesign:\n\nParticipants will fill out a questionnaire. Topics will include their medical history and foods they eat.\n\nParticipants will be asked to give 1 or more of the following:\n\nStool, urine, saliva, vaginal fluid, and breastmilk. These samples can be collected at home and sent to the researchers.\n\nCells from participants cheek, nose, mouth, skin, rectum, and\u002For vagina. The cells may be collected by rubbing the area with a sterile cotton swab. These procedures can also be done at home.\n\nBlood. Blood may be drawn using a needle inserted into a vein in the arm. For young children, blood may be collected by a prick on the heel or finger.\n\nIntestinal tissue samples. These may be collected from participants who are having an endoscopy or colonoscopy for other reasons.\n\nSkin tissue samples. These may be collected from participants who are having biopsies for other reasons.",[72,73,74,75],"Healthy Controls","Pregnancy","Pediatric Illnesses","Inflammatory Diseases",[77,78,79,73,80],"Microbiome","Host Response","Children","Natural History","2026-06-27",{"date":49,"type":52},{"date":84,"type":52},"2023-03-09",{"date":86,"type":23},"2032-01-01",{"name":88,"class":89},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":17,"sex":18,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":24,"phases":101,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":90},"100633794","phase-1-safety-and-tolerability-study-of-vvz-2471-in-healthy-volunteers-100633794","NCT07531316","Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers","Inclusion Criteria\n\nParticipants must meet all of the following criteria to be eligible for the study:\n\n1. Demographics: Male or female, between 18 and 65 years of age.\n2. High Impulsivity: Must demonstrate high impulsivity during the screening period, defined as an Immediate Memory Task (IMT) Commission Error by Correct Deletions (CE\u002FCD) ratio \\> 0.25.\n3. Informed Consent: Able to understand study procedures, follow instructions, and provide written informed consent in the English language.\n4. Health Status: Be in generally good health based on medical history, physical exam, clinical laboratory values, vital signs, and ECG done during the screening period, as deemed by the Principal Investigator (PI) or designee.\n5. Vital Signs (Resting): Resting pulse between 55 and 95 bpm; Systolic Blood Pressure between 90-120 mmHg; Diastolic Blood Pressure between 50-80 mmHg.\n6. Vital Signs (Orthostatic): A set of orthostatic vital signs completed during screening and on each study visit demonstrating a decrease in Systolic Blood Pressure\\\u003C 20 mmHg and Diastolic Blood Pressure \\\u003C10 mmHg upon standing.\n7. BMI: Body Mass Index between 18.5 and 35 kg\u002Fm².\n8. Toxicology: Urine drug test negative for non-prescribed substances and a breath (or oral fluid) alcohol screen negative during screening.\n9. Cardiac Safety: QTcF interval \\\u003C 450 ms and ECG findings considered normal or not clinically significant at screening by the PI\u002Fdesignee.\n10. Laboratory Values: Clinical labs completed during screening must meet the following safety thresholds:\n\n    * Serum creatinine, AST, ALT, BUN: \\\u003C 1.5 x Upper Limit of Normal (ULN)\n    * Platelet count: \\>140 x 10⁹\u002FL\n    * INR: \\\u003C 1.2\n    * PT\u002FaPTT: \\\u003C 1.2 x ULN\n    * Fibrinogen: \\> 175 mg\u002FdL\n11. Female Participants: Must not be of childbearing potential. They must be either post-menopausal or surgically sterile. They must not be pregnant or breastfeeding.\n12. Male Participants: Male subjects of reproductive potential must use a highly effective contraceptive method from first dose through 90 days after the last dose and to refrain from sperm donation during the same period.\n\nExclusion Criteria\n\nParticipants meeting any of the following criteria will be excluded:\n\nPsychiatric \\& Substance Use\n\n1. Psychosis and bipolar disorder: Any lifetime history of psychosis or bipolar disorder.\n2. Current Psychiatric Disorder: Current or recent (within the last year) DSM-5 diagnosis of any other psychiatric disorder that would make study participation unsafe, including but not limited to depressive disorders, trauma- or stress related disorders, and anxiety disorders that in the opinion of the investigator would make study participation unsafe.\n3. Substance Use Disorder: Current DSM-5 diagnosis (any severity) of an alcohol or drug use disorder, or use of illicit\u002Fnon-prescribed substances within the last 12 months.\n\n   o Note: Tobacco use disorder is not considered exclusionary.\n4. Suicidality: Current or recent suicidal or homicidal ideation (C-SSRS \"yes\" answers on any questions) or a history of suicide attempt within the past 12 months.\n\n   Medical \\& Neurological\n5. Neurological Disorders: History of neurological disorders including epilepsy or a family history of epilepsy, intractable\u002Fcomplicated migraine syndromes, cluster headache syndrome, extrapyramidal\u002Fpyramidal disorders, cerebrovascular, or degenerative disorders.\n6. Seizure History: Any lifetime history of seizure.\n7. Traumatic Brain Injury (TBI): Lifetime history of brain injury with loss of consciousness \\> 30 minutes, Past-year brain injury with loss of consciousness \\\u003C 30 minutes.\n8. Cardiovascular Conditions: History of heart failure, cardiomyopathy, sick sinus syndrome, second or third-degree AV block, myocardial infarction, pulmonary congestion, symptomatic\u002Fsignificant cardiac arrhythmia, or clinically significant abnormal conduction on baseline ECG.\n9. Bleeding \\& Coagulation: Recent history (within 6 months) of clinically significant bleeding; or history of intracranial hemorrhage, subdural\u002Fepidural hematoma, hemorrhagic stroke, AVM, or bleeding diatheses.\n10. Systemic Disease: History of malignancy (cancer), or significant respiratory, gastrointestinal, renal, urological, reproductive, endocrine, dermatological, or metabolic disorders.11. Liver\u002FPancreas: Pancreatic or liver disease that currently requires medical treatment.\n\n12\\. Positive HIV, HCV or HBC test results indicative of HIV infection or active hepatitis B or hepatitis C infection.\n\nMedications \\& Interactions 13. CYP3A4 Interactions: Currently taking prescription\u002FOTC drugs or supplements known to significantly inhibit CYP3A4 (e.g., clarithromycin, ketoconazole, ritonavir, grapefruit juice) or induce CYP3A4 (e.g., phenobarbital, rifampicin, St. John's Wort).\n\n14\\. CNS Active Medications: Currently taking a 5-HT2AR or mGluR5 antagonist or other CNS active medications that may increase risk as deemed by the PI or designee (e.g., antidepressants, antipsychotics, mood stabilizers, anticonvulsants, opioids, CGRP antagonists, triptans, ergotamines, or anxiolytics).\n\n15\\. Study Drug History: Any previous medically adverse reaction to a 5-HT2AR or mGluR5 antagonist.\n\n16\\. Concurrent Trials: Participation in another clinical trial with study medication administration within 30 days prior to first dosing.\n\nOther 17. General Safety: Any current, uncontrolled clinically significant medical condition that would make study participation unsafe, as deemed by the PI or designee.","18 Years","65 Years",{"count":100,"type":23},60,[102],"PHASE1","The goal of this study is to do follow-up safety testing and how well people are able tolerate an experimental (not FDA approved) medication . This study is seeking non-illicit drug using adults to test the medication. Results of this study will help us to develop future studies to test the medication with people who use substances.",[72],"NOT_YET_RECRUITING","2026-06-23",{"date":108,"type":52},"2026-06-25",{"date":110,"type":23},"2026-07-15",{"date":112,"type":23},"2031-12-30",{"name":114,"class":59},"Virginia Commonwealth University",{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":17,"sex":18,"minAge":97,"maxAge":4,"enrollmentInfo":123,"targetDuration":125,"studyType":69,"phases":4,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":90},"100641351","exploring-the-genetics-of-schizophrenia-in-manitoba-100641351","NCT07656870","Exploring the Genetics of Schizophrenia in Manitoba","Uncovering Schizophrenia Genetics Through Whole Genome Sequencing Across Manitoba","GENES-MB","Inclusion Criteria:\n\n* Individuals aged 18 years and older,\n* Reside in Manitoba,\n* Involved in the EPPIS, STEP, PACT, ACT\u002FFACTT clinics,\n* Clinical diagnosis of schizophrenia using standard DSM-5 criteria,\n* Previously consented and enrolled in the MPR.\n\nExclusion Criteria:\n\n* There are no specific exclusion criteria beyond meeting the inclusion criteria or not providing informed consent.",{"count":124,"type":23},1500,"1 Year","Schizophrenia is a serious mental illness that affects about 1 in 100 Canadians, shortens life expectancy, and places a large burden on individuals, families, and the healthcare system. Genetics are known to play a major role, but current research explains only part of the inherited risk because most studies have looked at only a small portion of the genome and have mainly focused on people outside Canada. This project will create the first large-scale Manitoba-based schizophrenia whole-genome sequencing database by studying 1,500 Manitobans with and without schizophrenia using both short-read and advanced long-read genome sequencing technologies. Researchers will combine genetic data with lifelong provincial health records to better understand rare genetic variants linked to schizophrenia and how genetic differences influence medication response, side effects, hospitalizations, and treatment outcomes. The study aims to fill important gaps in schizophrenia research in Canada, improve understanding of the disorder's biology, and support the development of more personalized and effective treatments for people living with schizophrenia.",[128,30],"Schizophrenia",[130,131,132,133,134],"schizophrenia","genetics","saliva","genome","sequencing","2026-06-12",{"date":137,"type":52},"2026-06-18",{"date":139,"type":23},"2026-08",{"date":141,"type":23},"2031-04",{"name":143,"class":59},"University of Manitoba",{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":17,"sex":18,"minAge":97,"maxAge":19,"enrollmentInfo":151,"targetDuration":4,"studyType":24,"phases":153,"briefSummary":154,"conditions":155,"keywords":159,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":90},"100593968","a-pet-mri-study-of-serotoninergic-brainstem-pathway-in-patients-with-dravet-syndrome-100593968","NCT07013331","A PET-MRI Study of Serotoninergic Brainstem Pathway in Patients With Dravet Syndrome","DRAPETONINE","Patients with DS\n\n* Inclusion criteria\n\n  1. Adult patients (≥ 18 but \\\u003C 60 years)\n  2. Diagnosis of Dravet syndrome will be confirmed based on medical history, type of seizures, EEG data and results of genetic testing\n  3. No restriction related to the seizure frequency\n  4. Patient assent and patient (or patient's legal representative guardianship) who gave its written informed consent to participate to the study\n  5. For women of childbearing\n* Exclusion criteria\n\n  1. Subject in exclusion period of another study\n  2. MRI contra-indication (presence of metallic elements, claustrophobia, Patients unable to maintain a minimul level of immobility during the imaging acquisition)\n  3. Presence of Vagal Nerve Stimulation\n  4. Patients unable to maintain a minimul level of immobility during the imaging acquisition\n  5. Pregnant women, women in labor or breastfeeding women.\n  6. Severe renal failure (Glomerular filtration rate \\\u003C 30 ml\u002Fmin)\n  7. Hypersensitivity to \\[18F\\] MPPF\n  8. Persons deprived of their liberty by a judicial or administrative decision\n  9. Persons under psychiatric care\n  10. Persons not affiliated to a social security scheme or beneficiaries of a similar scheme\n\nPatients with drug-resistant focal epilepsy\n\n* Inclusion criteria\n\n  1. Adult patient (≥ 18 years)\n  2. Patient suffering from drug-resistant focal epilepsy according to ILAE classification\n  3. Patient in whom presurgical evaluation is considered\n  4. No restriction related to the seizure frequency\n  5. Patient who gave her\u002Fhis written informed consent to participate to the study\n  6. For women of childbearing potential, use highly effective contraception during study participation\n* Exclusion criteria\n\n  1. Subject in exclusion period of another study\n  2. MRI contra-indication (presence of metallic elements, claustrophobia)\n  3. Presence of Vagal Nerve Stimulation\n  4. Ongoing serotoninergic treatment, including selective serotonin reuptake inhibitor\n  5. Pregnant women, women in labor or breastfeeding women.\n  6. Severe renal failure (Glomerular filtration rate \\\u003C 30 ml\u002Fmin)\n  7. Hypersensitivity to \\[18F\\] MPPF\n  8. Persons deprived of their liberty by a judicial or administrative decision\n  9. Persons under psychiatric care\n  10. Persons admitted to a health or social institution for purposes other than research\n  11. Adults subject to a legal protection measure (guardianship, curatorship)\n  12. Persons not affiliated to a social security scheme or beneficiaries of a similar scheme\n\nHealthy controls\n\n* Inclusion criteria\n\n  1. Presence of the symptoms of anxiety and\u002For depression as defined by a score ≥ 11 at the French version of the Hospital Anxiety and Depression Scale (HADS)\n  2. Ongoing treatment with selective serotonin reuptake inhibitor\n  3. MRI contra-indication (presence of metallic elements, claustrophobia)\n  4. Pregnant women, women in labor or breastfeeding women.\n  5. Severe renal failure (Glomerular filtration rate \\\u003C 30 ml\u002Fmin)\n  6. Hypersensitivity to \\[18F\\] MPPF\n  7. Persons deprived of their liberty by a judicial or administrative decision\n  8. Persons under psychiatric care\n  9. Persons admitted to a health or social institution for purposes other than research\n  10. Adults subject to a legal protection measure (guardianship, curatorship)\n  11. Persons not affiliated to a social security scheme or beneficiaries of a similar scheme\n* Exclusion criteria\n\n  1. Presence of the symptoms of anxiety and\u002For depression as defined by a score ≥ 11 at the French version of the Hospital Anxiety and Depression Scale (HADS)\n  2. Ongoing treatment with selective serotonin reuptake inhibitor\n  3. MRI contra-indication (presence of metallic elements, claustrophobia)\n  4. Pregnant women, women in labor or breastfeeding women.\n  5. Severe renal failure (Glomerular filtration rate \\\u003C 30 ml\u002Fmin)\n  6. Hypersensitivity to \\[18F\\] MPPF\n  7. Persons deprived of their liberty by a judicial or administrative decision\n  8. Persons under psychiatric care\n  9. Persons admitted to a health or social institution for purposes other than research\n  10. Adults subject to a legal protection measure (guardianship, curatorship)\n  11. Persons not affiliated to a social security scheme or beneficiaries of a similar scheme",{"count":152,"type":23},30,[26],"Dravet Syndrome (DS) is a severe neurodevelopmental disease, which is predominantly caused by mutations of SCN1A, the gene coding for Nav1.1 voltage-gated sodium channels. DS is characterized by infancy onset, severe cognitive deficit and drug-resistant seizures, including several generalized convulsive seizures per day and frequent status epilepticus, often triggered by fever or hyperthermia. Among the causes of premature deaths in patients with epilepsy, sudden and unexpected death in epilepsy (SUDEP) represents a major cause. SUDEP is a non-traumatic and non-drowning death in patients with epilepsy, unrelated to a documented status epilepticus. The risk of SUDEP is particularly high in patients suffering from DS, reaching about 9\u002F1000-person-year, as compared to about 1\u002F1000-person-year in people with epilepsy including all disease types. The main clinical risk factor of SUDEP is the frequency of convulsive seizures. Beyond improving seizure control, which we showed to mitigate the SUDEP risk, more specific preventive treatment strategies are still lacking.\n\nExperimental and clinical data suggest that most SUDEP cases result from postictal brainstem dysfunction, including central respiratory arrest There is a body of evidence suggesting involvement of serotonin (5HT) dysfunction both in the pathogenesis of epilepsy in DS and in seizure-related respiratory dysfunction. Serotonin indeed plays a key role in the regulation of respiration. Population firing of serotoninergic neurons in the medullary raphe is significantly decreased during the ictal and post-ictal periods, in association with decreased breathing and heart rate during and after seizures. Most importantly, post-mortem data in patients, including DS, showed alteration of neuronal populations in the medulla in SUDEP cases with evidence for greater reduction in neuromodulatory neuropeptidergic and monoaminergic, including serotoninergic, systems.\n\nSUDEP in DS might therefore be the result of a seizure-induced fatal apnea in a patient who has developed epilepsy-related vulnerability to central respiratory dysfunction favored by 5HT dysfunction. However, several issues remain to be addressed to identify detailed mechanisms and effective therapies. Among them, a key issue is the exact relation between the alterations of the 5HT pathway observed in DS and epilepsy-related respiratory dysfunction\n\nIn the present study, the hypothesis is that adult patients with DS might demonstrate specific alterations of the 5HT pathway within the brainstem as assessed by PET imaging. The DRAPETOTINE study will thus focus on imaging 5HT brainstem pathway with PET and MRI in patients with DS to assess if abnormalities can be observed and through comparison with data collected in patients drug-resistant focal epilepsy whether these abnormalities are DS specficic or reflect the consequence on brainstem 5HT pathway of refractory seizures.\n\nThis study will involve 20 adult patients, including 10 adults with established diagnosis of Dravet Syndrome and 10 patients with drug-resistant focal epilepsy. Ten healthy adults will also be included. Participants will be recruited over a period of 18 months and the duration of participation for each participant will be 2 weeks to 8 weeks",[156,157,158,72],"Epilepsy","Dravet Syndrome","Drug Resistant Epilepsy",[160,161,162,163,164,165,166],"epilepsy","Dravet syndrome","drug-resistant focal epilepsy","serotonin","PET-MRI","MPPF","SUDEP","2026-05-05",{"date":169,"type":52},"2026-05-08",{"date":171,"type":52},"2026-05-04",{"date":173,"type":23},"2028-01-04",{"name":175,"class":59},"Hospices Civils de Lyon",{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":17,"sex":18,"minAge":97,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":24,"phases":187,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":90},"100562766","temporal-interference-stimulation-for-social-cognition-100562766","NCT06607432","Temporal Interference Stimulation for Social Cognition","Use of Alpha-frequency Deep Transcranial Interference Stimulation (tIS) to Understand and Modify Temporal Dynamics of Face Emotion Recognition and Social\u002FAffective Function","TISSC","Inclusion Criteria:\n\n* Male or female\n* Age 18-55 years\n* Wechsler Adult Intelligence Scale (WAIS) intelligence quotient (IQ) \\>70\n* Competent and willing to sign informed consent.\n* Shall not have been prescribed any standing medications for treatment of a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Axis I psychiatric disorders within 90 days of the study and shall not have been prescribed standing opioid analgesic, anticonvulsant, antidementia, antidepressant, antimigraine, antipsychotic, anxiolytic, bipolar agents, central nervous system agents, or sedative\u002Fhypnotics within 90 days of the study even if for a non-psychiatric indication. Intermittent use of sedative\u002Fhypnotic medications is permitted, but these agents shall not be used within 48 hours of the tIS administration.\n* Healthy relative to age-dependent expectation as determined by medical history and physical examination within 90 days of enrollment.\n\nExclusion Criteria:\n\n* Has a history of an illness, disease, condition injury, or disability which, in the opinion of the principal investigator (PI), may interfere with the completion of all study requirements per protocol, impact the quality of the data, or the validity of the study results.\n* Contraindication to MRI (e.g. metal implants, claustrophobia, pregnancy)\n* On the Columbia-Suicide Severity Rating Scale (C-SSRS) Screen Version-Recent, answers YES to Question 3 and NO to Question 6 (Moderate Risk) or answers YES to Question 4, 5, or 6 (High Risk).\n* Presence or positive history of significant medical illnesses, including high blood pressure(defined as systolic blood pressure (SBP) \\>140 or diastolic blood pressure (DBP) \\>90, low blood pressure (SBP \\\u003C100, DBP \\\u003C60), orthostatic blood pressure as baseline (change in mean arterial pressure \\[1\u002F3 systolic + 2\u002F3 diastolic\\] of \\>20%), cardiac illness, or clinical significant abnormal electrocardiogram (EKG), as determined by the site physician\n* Women of childbearing potential who, at enrollment or during the study:\n\n  * have a positive urine pregnancy test or a self-reported pregnancy;\n  * are heterosexually active without usage of a medically acceptable, highly effective contraceptive method\\* ( 1% pregnancy rate); or\n  * are planning to become pregnant during the course of this study, as determined by the PI, are excluded from study participation. Examples include tubal ligation, vasectomized partner, intrauterine device (IUD) or intrauterine system (IUS), and longacting reversible contraceptives (LARC).","55 Years",{"count":186,"type":23},10,[26],"The long-term goal of this project is to evaluate whether a procedure termed transcranial interference stimulation (tIS) may be useful in the future in the treatment of severe neuropsychiatric disorders such as schizophrenia. The purpose of this stage of the project is to evaluate the safety and tolerability of tIS administration in healthy volunteers.\n\nThis study involves 10 healthy participants without known psychiatric illness X 3 successive doses. Participants may participate in 1-3 doses, yielding a total sample size of 10-30 individuals across doses. The dose of tIS will be escalated progressively across doses. Functional magnetic resonance imaging (fMRI), magnetic resonance spectroscopy (MRS) and side effect checklists will be used to assess tIS safety\u002Ftolerability at each dose. In addition, electroencephalogram (EEG) will be collected simultaneously with tIS and used to assess target engagement. Face emotion recognition (FER) data will also be collected, but will be used for feasibility assessment only.\n\nIf successful, these studies will form the basis for future studies in schizophrenia.",[72],[191],"Transcranial Interference Stimulation","2026-04-20",{"date":194,"type":52},"2026-04-23",{"date":196,"type":52},"2025-03-03",{"date":198,"type":23},"2028-02-29",{"name":200,"class":59},"Columbia University",{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":17,"sex":18,"minAge":97,"maxAge":98,"enrollmentInfo":208,"targetDuration":4,"studyType":24,"phases":210,"briefSummary":211,"conditions":212,"keywords":214,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":90},"100609998","decoding-emotional-dynamics-in-bipolar-disorder-100609998","NCT07221864","Decoding Emotional Dynamics in Bipolar Disorder","Decoding Emotional Dynamics Driving Mood Instability in Bipolar Disorder","Inclusion Criteria\n\n1. Age 18 to 65 years\n2. Male or female\n3. BMI between 18.5 and 38.0 kg\u002Fm2 at Screening\n4. Capable of understanding and complying with study requirements\n5. Fluent in English\n6. Able to provide informed consent\n\n   BD Group:\n7. Meet the DSM-5 diagnostic criteria for BD-I or BD-II who are currently depressed or mixed state defined by the Mini-International Neuropsychiatric Interview (MINI)\n8. Moderate or greater depressive symptom severity (MADRS ≥ 15 or PHQ-9 ≥ 10)\n\n   HC Group:\n9. No current or past psychiatric disorder (verified by MINI)\n\nExclusion Criteria\n\n1. No telephone or easy access to a telephone\n2. Significant medical problems as identified by the medical screening questionnaire: e.g. a history of unstable liver or renal insufficiency; glaucoma; significant and unstable cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, or metabolic disturbance; or any other condition that, in the opinion of the investigator, would make participation not be in the best interest (e.g., compromise the well-being) of the participant or that could prevent, limit, or confound the protocol-specified assessments\n3. A positive test for drugs of abuse, including alcohol (breath test), cocaine, opiates, amphetamines, methamphetamines, phencyclidine, benzodiazepines, barbiturates, methadone, and oxycodone\n4. Drug or alcohol intoxication (based on positive UTOX or breathalyzer test at screening or study session) or reported alcohol\u002Fdrug withdrawal, last cannabis use must be \\>48 hours prior to study session.\n5. Current DSM-5 diagnosis of a psychosis spectrum disorder or moderate to severe substance use disorder\n6. Moderate to severe traumatic brain injury or other neurocognitive disorder with evidence of neurological deficits, neurological disorders, or severe or unstable medical conditions that might be compromised by participation in the study (to be determined by primary care provider)\n7. Current significant suicidal ideation or suicide attempt within the past 3 months.\n8. Change in the dose or prescription of a medication within the 6 weeks before enrolling in the study that could affect brain functioning, e.g., anxiolytics, antipsychotics, antidepressants, or mood stabilizers\n9. Taking drugs that affect the fMRI hemodynamic response (e.g., methylphenidate, acetazolamide, excessive caffeine intake \\> 1000 mg\u002Fday)\n10. MRI contraindications as documented on the MR Environment Screening\n11. Unwillingness or inability to complete any of the major aspects of the study protocol, including magnetic resonance imaging (i.e., due to claustrophobia), or behavioral assessment. However, failing to complete some individual aspects of these assessment sessions will be acceptable (i.e., being unwilling to answer individual items on some questionnaires or being unwilling to complete a behavioral task)\n12. Non-correctable vision or hearing problems",{"count":209,"type":23},72,[26],"The goal of this neuroimaging study is to investigate how emotional states fluctuate in people with bipolar disorder (BD) compared to healthy controls, and to understand the neural mechanisms driving mood instability. The main questions it aims to answer are:\n\n* Can emotional states be decoded from fMRI brain activity using machine learning?\n* Do individuals with BD show more unstable emotional state trajectories (e.g., high metastability, low fractal scaling) than healthy controls?\n* Does amplifying positive emotions stabilize brain and emotional dynamics in BD?\n\nResearchers will compare individuals with bipolar disorder (BD-I or BD-II, currently depressed or mixed state) to healthy controls without psychiatric history to see whether the BD group shows greater fluctuations in emotional brain activity and whether positive emotion regulation strategies normalize this instability.\n\nParticipants will:\n\n* Complete self-report questionnaires on mood, emotion regulation, anxiety, and daily functioning.\n* Recall and provide short descriptions of personal positive and negative memories to be used in the MRI task.\n* Undergo fMRI scanning, including:\n* Resting-state scans\n* A Think and Regulate Affective States Task (TReAT) where they recall autobiographical memories, rate emotions, and practice amplifying positive mood.\n* Structural and diffusion MRI for brain mapping.\n* Receive physiological monitoring (heart rate, respiration) during scanning.\n* Complete post-scan surveys on emotional state and task experience.\n\nThis research will help clarify how the brain supports or disrupts emotional regulation in bipolar disorder and may inform the development of personalized, neurobiologically informed treatments for mood instability.",[213,30],"Bipolar Disorder I or II",[215,216,217,218,219,220],"neuroimaging","fMRI","Bipolar Disorder I","Bipolar Disorder II","machine learning","emotion regulation","2026-04-15",{"date":223,"type":52},"2026-04-17",{"date":225,"type":52},"2025-10-30",{"date":227,"type":23},"2028-11",{"name":229,"class":59},"Laureate Institute for Brain Research, Inc.",{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":17,"sex":238,"minAge":97,"maxAge":239,"enrollmentInfo":240,"targetDuration":4,"studyType":24,"phases":241,"briefSummary":242,"conditions":243,"keywords":247,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":90},"100591340","pilot-study-of-personalized-aperiodic-transcranial-alternating-current-stimulation-in-antenatal-depression-panda-tacs-100591340","NCT06979154","Pilot Study of Personalized Aperiodic Transcranial Alternating Current Stimulation in Antenatal Depression (PandA-tACS)","Pilot Study Using Endogenous Aperiodic Brain Activity to Personalize Transcranial Alternating Current Stimulation as a Treatment for Antenatal Depression: PandA-tACS","PandA-tACS","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Female aged 18 - 45\n* Capacity to understand all relevant risks and potential benefits of the study as determined by study staff (provision of informed consent)\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Low suicide risk (defined for this study as no active suicidal ideation in the past month and no suicide attempts, preparatory actions, or significant non-suicidal self-harm in the previous 2 years). Risk will be assessed utilizing the C-SSRS screen and triage version with further exploration of positive responses.\n\nFor healthy control population:\n\n* Use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation, according to NIH Therapeutics Research Program Guidelines.\n\nAdditional for antenatal depression population:\n\n* Between weeks 14-32 of viable singleton pregnancy\n* Established obstetric care through UNC\n* Pre-identified DSM-5 diagnosis of unipolar, non-psychotic MDD which is confirmed by the DIAMOND\n* HDRS-17 score ≥8\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* DSM-5 diagnosis of severe alcohol use disorder (AUD) within the last 12 months, as evidenced by the DIAMOND\n* DSM-5 diagnosis of moderate to severe substance use disorder (excluding tobacco) within the last 12 months, as evidenced by the DIAMOND\n* Lifetime history of bipolar disorder, as evidenced by DIAMOND\n* Schizophrenia spectrum and other psychotic disorders, as evidenced by DIAMOND\n* History of autism spectrum disorder\n* Initiated any new psychotropic medication in the 6 weeks prior to screening or had a dose change in the preceding 6 weeks\n* Initiated a new course of psychotherapy in the 6 weeks preceding screening\n* Received any neurostimulation treatment in the 6 weeks preceding screening\n* History of seizures (excluding febrile seizures in childhood or Electroconvulsive Therapy (ECT) induced seizures)\n* Neurological disorders that would increase risk of participation or present a significant confounder in the opinion of the investigator (for example, dementia, history of stroke, Parkinson's disease, multiple sclerosis, history of traumatic brain injury with prolonged loss of consciousness, ruptured cerebral aneurysm, previous CNS radiation)\n* Previously failed to respond to ECT or transcranial magnetic stimulation (TMS)\n* Prior brain surgery and\u002For brain implants\n* Implanted medical device that uses electricity\n* Currently enrolled in another clinical trial for depression\n* Unstable medical disorder or anything that would place the participant at increased risk or preclude the participant's full compliance with or completion of the study, in the opinion of the Investigator\n\nAdditional for the healthy control population:\n\n* Current pregnancy or lactation (as determined by urine pregnancy test)\n* History of depression, as evidenced by DIAMOND\n\nAdditional for the antenatal depression population:\n\n* History of any of the following conditions:\n\n  * Diabetes (gestational or general history)\n  * Pre-term delivery (\\\u003C37 weeks)\n  * Eclampsia\n  * Pre-eclampsia with severe features\n  * Asthma requiring daily medication\n  * Chronic hypertension\n  * Immune thrombocytopenia (ITP)\n  * Hyperthyroidism requiring medication\n  * Pre-pregnancy BMI 40 or more\n  * In vitro fertilization (IVF)\n  * Mullerian anomaly of uterus\n  * Organ transplant\n  * Prior history of deep vein thrombosis\u002Fpulmonary embolism (DVT\u002FPE) or plan for anticoagulation during pregnancy\n  * Fetus with autoimmune hydrops\n  * Abnormal placenta\n* Current pregnancy:\n\n  * HIV\u002FHep B\u002FHep C with detectable viral loads\n  * Anemia \\[Hemoglobin under 11.0\\] upon entry to prenatal care\n  * No scheduled prenatal visits by 15 weeks\n  * Placenta previa\n  * Placenta accreta spectrum (PAS)\n  * Pre-eclampsia\n  * Gestational diabetes\n  * Gestational hypertension\n  * Fetus with abnormal chromosomes\n  * Cervical length \\\u003C 2.5 cm\n  * Presence of cerclage or vaginal progesterone to decrease chance of pre-term labor\n  * Fetal growth restriction\n  * Macrosomia\n  * Polyhydramnios\n  * Oligohydramnios\n  * Rupture of membranes\n  * Hyperemesis Gravidarum (HEG)\n  * Confirmation testing for Tri 13\u002F18\u002F21\n  * Congenital anomalies on anatomy ultrasound that do not resolve with follow-up ultrasound\n* Other cause of markedly high-risk pregnancy as determined by the Investigator","FEMALE","45 Years",{"count":186,"type":23},[26],"The purpose of this study is to develop the safety, feasibility, and tolerability of a personalized transcranial alternating current stimulation (tACS) approach in antenatal depression.",[244,245,246,72],"Antenatal Depression","Major Depressive Disorder","Major Depressive Disorder in Pregnancy",[248,249,250,251,252,245,253,254,73,255,256,257,258,259,260,72,261],"Behavioral Symptoms","Mood Disorders","Mental Disorders","Depression","Depressive Disorder","Antenatal diagnoses","Prenatal diagnoses","Electric Stimulation","non-invasive brain stimulation","transcranial alternating current stimulation","tACS","EEG","antenatal depression","Aperiodic brain activity","2026-04-08",{"date":264,"type":52},"2026-04-09",{"date":266,"type":52},"2025-08-12",{"date":268,"type":23},"2026-12-01",{"name":270,"class":59},"University of North Carolina, Chapel Hill",{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":17,"sex":18,"minAge":97,"maxAge":278,"enrollmentInfo":279,"targetDuration":4,"studyType":24,"phases":281,"briefSummary":283,"conditions":284,"keywords":287,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":90},"100614822","phase-2-ultralow-dose-pet-imaging-of-sstr2-radiotracer-uptake-100614822","NCT07284589","Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake","Evaluation of Ultralow Dose PET Imaging for Detecting SSTR2 Radiotracer Uptake","Inclusion Criteria:\n\n* Age ≥18 years.\n* Ability to provide informed consent and comply with study procedures.\n* For female participants: Must not be pregnant or breastfeeding; Negative pregnancy test required for women of childbearing potential.\n\nExclusion Criteria:\n\n* Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 millisievert \\[mSv\\] total).\n* More than four prior enrollments in this study.\n* Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan\n* Medication \\& Prior Treatment Exclusions: SSTR targeted therapies\n* Pregnant or breastfeeding individuals (negative pregnancy test required)\n* Inability to provide informed consent\n* Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.","120 Years",{"count":280,"type":23},200,[282],"PHASE2","The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET) imaging technique for neuroendocrine tumor detection and monitoring. The main question it aims to answer is:\n\nCan the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer that binds to a tumor specific protein called somatostatin receptor 2 (SSTR2) and be imaged on a new type of high sensitivity PET scanner for up to 3 hours",[30,285,286],"Healthy Volunteers","Neuroendocrine (NE) Tumors",[288,289,290,291,292,293,294],"PET","PET\u002FCT","SSTR2","neuroendocrine","dotatate","low dose","nuclear imaging","2026-04-07",{"date":262,"type":52},{"date":298,"type":52},"2025-12-11",{"date":300,"type":23},"2030-04-30",{"name":302,"class":59},"Akiva Mintz",{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":17,"sex":18,"minAge":97,"maxAge":309,"enrollmentInfo":310,"targetDuration":4,"studyType":24,"phases":312,"briefSummary":314,"conditions":315,"keywords":318,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":326,"leadSponsor":328,"locationsCount":90},"100601342","phase-4-do-antipsychotics-block-insulin-action-in-the-brain-is-it-a-class-effect-100601342","NCT07109245","Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect?","Inclusion Criteria:\n\n1. Must be deemed to have the capacity to provide informed consent\n2. Must sign and date the informed consent form\n3. Stated willingness to comply with all study procedures;\n4. Age: 18-35\n5. Body Mass Index (BMI) 18.5-24.9 kg\u002Fm2\n6. Both sexes\n\nExclusion Criteria:\n\n1. History of psychiatric illness, including any substance use (screened using the Mini International Neuropsychiatric Interview (MINI))\n2. Pre-diabetes or diabetes (fasting glucose ≥6.0 mmol\u002FL, HbA1c\\>6% or use of anti-diabetic drug),\n3. Evidence of impaired insulin sensitivity, assessed using the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) ≥2.5\n4. Family history of diabetes in a first degree relative (parent or sibling)\n5. Use of weight reducing agents\n6. History of kidney or liver disease\n7. History of cell blood disorders\n8. Irregular menstrual cycles (e.g., menstruation occurs less than 21 days or more than 35 days apart, or not having menstruated for three months (or 90 days), or conditions such as endometriosis or polycystic ovary syndrome (PCOS) or prior surgical interventions such as a hysterectomy or oophorectomy)\n9. Current use of hormonal birth control (e.g., pill, patch, hormonal intrauterine device \\[IUD\\], ring). Participants must have had at least 2 regular menstrual cycles following the discontinuation of hormonal birth control \\[50\\]\n10. Current use of progesterone, estrogen, testosterone, or fertility treatment.\n11. Pregnant, gave birth in the last year, or breastfeeding. Participants must have at least 3 regular menstrual cycles post-breastfeeding before beginning the study.\n12. Major medical or surgical event within the last 6 months\n13. Contraindications for MRI, including metal implants, pacemakers, cochlear implants, claustrophobia, weight \\>250 lbs\n14. Any contraindications to the investigational products as listed in the product monographs including known hypersensitivity to the drug or the excipients of the product (note: enzymatic lactose intolerance is NOT exclusionary),\n15. Any medications that increases risk of hypoglycemia or could contribute to hyperglycemia\n16. Any medical conditions that constitute as a warning\u002Fprecaution for haloperidol, lorazepam, benztropine, or insulin.\n17. Use of any of the prohibited medications listed in the product monograph of haloperidol, lorazepam, benztropine, or insulin (Pheochromocytoma, barbiturates, and narcotics are exclusionary, any use of painkillers and antihistamines must be reviewed by PI but are not exclusionary","35 Years",{"count":311,"type":23},35,[313],"PHASE4","This study aimed at helping researchers understand how a medication called haloperidol can affect insulin action in the brain. Insulin is a hormone in the body that controls sugar levels in part by lowering the amount of glucose produced by the liver. After eating a meal, insulin levels go up in both the blood and the brain. Insulin in the brain has also been shown to affect the way the brain works and processes information (also known as \"cognition\"). Haloperidol, is an antipsychotic medication used to treat a variety of disorders such as schizophrenia spectrum disorders, bipolar disorder, and major depressive disorder, but long-term use can have metabolic side effects, like weight gain, type 2 diabetes, and cardiovascular disease. The purpose of this study is to investigate how antipsychotic medications, such as haloperidol, which carries the risk of metabolic changes, might interrupt the effect of insulin action in the brain. This will help researchers learn how to potentially reduce metabolic risk for people who take these kinds of medications in the future.",[316,72,317],"Brain Insulin Sensitivity","Cognition",[316,319,320,317,321],"Healthy Control Study","Haloperidol","MRI","2026-03-30",{"date":324,"type":52},"2026-04-02",{"date":298,"type":52},{"date":327,"type":23},"2028-12",{"name":329,"class":59},"Centre for Addiction and Mental Health",{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":17,"sex":18,"minAge":336,"maxAge":337,"enrollmentInfo":338,"targetDuration":4,"studyType":24,"phases":340,"briefSummary":341,"conditions":342,"keywords":346,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":90},"100572374","subthreshold-vestibular-stimulation-as-a-strategy-for-rehabilitation-100572374","NCT06732440","Subthreshold Vestibular Stimulation as a Strategy for Rehabilitation","Inclusion Criteria for Bilateral Vestibular Hypofunction:\n\n1\\. Bilateral lateral canal VOR gain of \\\u003C 0.8 on video head impulse testing OR bilateral positive bedside head impulse test\n\nInclusion Criteria for Unilateral Vestibular Hypofunction:\n\n1\\. Unilateral yaw aVOR gain of \\\u003C 0.8 on video head impulse testing OR unilateral positive bedside head impulse test\n\nInclusion Criteria for all Participants:\n\n1. Must be able to stand for 5 minutes unassisted\n2. No leg or foot amputations\n3. No lower limb braces\n4. Not currently pregnant by self-report\n5. Weight \\\u003C= 300 pounds (due to limitations of testing equipment)\n\nExclusion Criteria for all participants:\n\n1. Severe head trauma or traumatic brain injury\n2. History of seizures\n3. Alternative neurologic illness or condition known to impact vestibular or balance function (e.g., stroke, neurodegenerative disorders, demyelinating illness)\n4. Major psychiatric (e.g., panic disorder, psychosis, etc.) disorder\n5. Any of the following eye diseases or conditions: amblyopia (or \"lazy eye\") or history of amblyopia, diagnosis of age- related macular degeneration, retina dystrophy, glaucoma, cataracts,\n6. Recent (\\\u003C6 months) orthopedic injury that may affect test performance\n7. Recent surgery (\\\u003C 6 months) that may impact test performance.\n8. Other severe health problems (heart disease, pulmonary disease, cancer, etc.) that may affect test performance\n9. Due to potentially nauseogenic nature of some motions and to protect fetus and mother, pregnant women will also be excluded from this study\n\n   * Since the investigators cannot address every possible potential individual recruit in advance, additional exclusion criteria may be required.","19 Years","89 Years",{"count":339,"type":23},48,[26],"The nervous system responds to changes in external or internal conditions by altering the behavior of neurons through multiple forms of neural plasticity. A specific form of plasticity, \"homeostatic plasticity\", stabilizes neural activity by driving the excitability of neurons toward a \"set-point\" level of activity. Over the last six years, new data have come to light showing that the vestibular system also possess a robust capacity to modulate sensitivity to self-motion cues in response to prolonged periods of motion. Collectively, these studies have demonstrated a capacity to use motion perturbations (i.e., low, or high levels of vestibular stimulation) to dynamically adjust the sensitivity of the vestibular system on both the single neuron and behavioral levels. The ability to use subthreshold motion stimuli to drive plasticity in the vestibular system motivates this study. The investigators aim to determine the impact of subthreshold motion on (a) balance performance and (b) balance training in individuals with peripheral vestibular hypofunction.",[343,344,345,72],"Vestibular Hypofunction","Bilateral Vestibular Hypofunction","Presbyvestibulopathy",[344,347],"Vestibular Rehabilitation","2026-03-16",{"date":350,"type":52},"2026-03-17",{"date":352,"type":52},"2026-02-09",{"date":354,"type":23},"2026-12-31",{"name":356,"class":59},"Creighton University",{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":17,"sex":18,"minAge":363,"maxAge":337,"enrollmentInfo":364,"targetDuration":4,"studyType":24,"phases":366,"briefSummary":367,"conditions":368,"keywords":371,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":90},"100614799","phase-4-elucidating-the-role-of-cholinergic-degeneration-in-cognitive-fluctuations-in-lewy-body-dementia-100614799","NCT07284290","Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia","Inclusion Criteria:\n\nArm 1:\n\n* Age range: 50 ≤ age \\\u003C 90.\n* Diagnosis of dementia with Lewy bodies (DLB), Parkinson disease dementia (PDD), Parkinson disease with Mild Cognitive Impairment (PD-MCI), Mild Cognitive Impairment with Lewy bodies (MCI-LB).\n* DLB participants must fulfill criteria for clinically probable DLB based on the 2017 4th consensus report of the DLB consortium.\n* PDD participants must meet criteria for clinically probable PD according to the MDS Clinical Diagnostic Criteria for Parkinson's Disease and must also meet criteria for probable PDD based on the 2007 Movement Disorders Society clinical diagnostic criteria.\n* PD-MCI participants must meet criteria for clinically probable PD according to the MDS Clinical Diagnostic Criteria for Parkinson's Disease and meet criteria for Mild Cognitive Impairment on cognitive testing at screening.\n* MCI-LB participants with must meet established research criteria.\n* Capacity to provide informed consent or, if unable, availability of a legally authorized representative or guardian who can provide informed consent.\n* Availability of informant (for participants meeting criteria for dementia).\n* Ability and willingness to comply with the study-related procedures.\n* Fluent in spoken and written English (due to cognitive testing)\n\nExclusion Criteria:\n\nArm 1\n\n* History of cognitive disorder or psychiatric disorder other than that related to dementia with Lewy bodies or Parkinson disease dementia.\n* History of deep brain stimulation or any neurosurgical procedure.\n* History of structural brain disease or known significant cerebrovascular disease.\n* History of seizures or epilepsy and\u002For use of sodium channel blockers, i.e. carbamazepine, oxcarbazepine, phenytoin, topiramate, lamotrigine, felbamate, zonisamide, rufinamide, lacosamide, eslicarbazepine, and valproate.\n* Greater than two alcoholic drinks per day for men and one per day for women.\n* Regular use of benzodiazepines or barbiturates. (If benzodiazepines are taken as needed only, these medications cannot be taken within 5 half-lives of screening visit or between screening visit and EEG.)\n* Severe dementia (based on PI assessment of subject dependence level for instrumental activities of daily living)\n* Any contraindication to brain MRI.\n* Any medical condition that would interfere with ability to complete all study procedures.\n* Participants must not be pregnant, planning to become pregnant, or father a child for the duration of the study\n\nInclusion Criteria:\n\nArm 2 (Cholinesterase inhibitor cohort) inclusion criteria:\n\n* Completed Aim 1.\n* Clinical diagnosis of LBD (DLB or PDD) with CF.\n* Not taking a cholinesterase inhibitor and has not taken a cholinesterase inhibitor in the previous 90 days.\n* Ability and willingness to comply with the ChEI Cohort procedures (including galantamine administration), or a caregiver willing and able to ensure compliance.\n\nExclusion Criteria:\n\nArm 2 (Cholinesterase inhibitor cohort) exclusion criteria:\n\n* Severe hepatic impairment.\n* Renal failure.\n* Significant bradycardia (\\\u003C50 bpm) at screening or history of AV block.\n* Any contraindication to galantamine administration based on PI discretion.\n\nInclusion criteria:\n\nArm 3 (Healthy Controls)\n\n* Age range: 50 ≤ age \\\u003C 90.\n* Healthy controls should not have any known neurologic conditions that could interfere with study procedures or results.\n* Capacity to provide informed consent or, if unable, availability of a legally authorized representative or guardian who can provide informed consent.\n* Availability of informant (for participants meeting criteria for dementia).\n* Ability and willingness to comply with the study-related procedures.\n* Fluent in spoken and written English (due to cognitive testing).\n\nExclusion Criteria:\n\nArm 3 (Healthy Controls)\n\n* No History of cognitive disorder or psychiatric disorder other than that related to dementia with Lewy bodies or Parkinson disease dementia.\n* No History of deep brain stimulation or any neurosurgical procedure.\n* No History of structural brain disease or known significant cerebrovascular disease.\n* No History of seizures or epilepsy and\u002For use of sodium channel blockers, i.e. carbamazepine, oxcarbazepine, phenytoin, topiramate, lamotrigine, felbamate, zonisamide, rufinamide, lacosamide, eslicarbazepine, and valproate.\n* Any medical condition that would interfere with ability to complete all study procedures.\n* Participants must not be pregnant, planning to become pregnant, or father a child for the duration of the study","50 Years",{"count":365,"type":23},120,[313],"The proposed study aims to address the critical gaps in understanding the mechanisms of CF (Cognitive Fluctuations) by leveraging recently emerged molecular biomarkers, advanced neuroimaging techniques to assess measures of cholinergic degeneration, and synchronous EEG and assessments of attention. One of the overarching innovations of study is combining all of these assessments into one integrated research plan",[369,370,72],"Dementia With Lewy Bodies","Parkinson Disease Dementia",[372,373],"Parkinson Disease with Mild Cognitive Impairment","Mild Cognitive Impairment with Lewy Bodies","2026-03-04",{"date":376,"type":52},"2026-03-06",{"date":378,"type":52},"2025-12-08",{"date":380,"type":23},"2029-11",{"name":114,"class":59},{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":17,"sex":18,"minAge":363,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":389,"conditions":390,"keywords":392,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":60},"100614607","clinical-validity-of-the-danu-sports-system-for-gait-and-balance-assessment-in-parkinsons-disease-100614607","NCT07281794","Clinical Validity of the DANU Sports System for Gait and Balance Assessment in Parkinson's Disease","Parkinson's Group Inclusion Criteria:- Clinical diagnosis of Parkinson's by a movement disorder specialist according to UK brain bank criteria.\n\n* PD stages I-III (Hoehn and Yahr Rating Scale)\n* Able to attend Northumbria University, Newcastle Upon Tyne for study visits.\n* Able to walk and stand unassisted for a minimum of 2-minutes.\n* Aged 50 years old or over\n\nParkinson's Group Exclusion Criteria:\n\n* History of neurological disorders other than PD (e.g., Huntington's disease, stroke, traumatic brain injury, multiple sclerosis, Alzheimer's disease etc.)\n* Unable to walk or stand unaided.\n* Montreal Cognitive Assessment (MoCA) score \\\u003C 21\n* Significant issues unrelated to PD that may affect gait (e.g., musculoskeletal issues, back pain, recent surgery etc.)\n\nHealthy Control Inclusion Criteria:\n\n* Ability to attend Northumbria University, Newcastle Upon Tyne for study visits.\n* Aged 50 years old or over.\n* Able to walk and stand unassisted for a minimum of 2-minutes.\n\nHealthy Control Exclusion Criteria:\n\n* History of neurological disorders (e.g. Huntington's disease, stroke, traumatic brain injury, multiple sclerosis, Alzheimer's disease etc.)\n* Significant issues that may affect walking (e.g., musculoskeletal issues, back pain, recent surgery etc.)",{"count":100,"type":23},"This observational study aims to explore the use of the DANU Smart Socks for gait and balance assessment in people with Parkinson's (PwP). The study will compare walking and balance outcomes produced by DANU from people with Parkinson's (PwP) and a group of healthy individuals of similar age. The project aims to investigate if the gait and balance data collected are linked to measures of Parkinson's symptoms such as disease progression and cognitive abilities. Gait and balance outcomes will be obtained through one observational laboratory visit.",[391,30],"Parkinson Disease (PD)",[393,394,395],"DANU","Clinical Validation","Wearable Electronic Devices","2026-02-11",{"date":398,"type":52},"2026-02-12",{"date":400,"type":52},"2025-08-08",{"date":402,"type":23},"2027-09",{"name":404,"class":59},"Northumbria University",{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":18,"minAge":97,"maxAge":412,"enrollmentInfo":413,"targetDuration":4,"studyType":24,"phases":414,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":418,"startDateStruct":419,"completionDateStruct":420,"leadSponsor":422,"locationsCount":90},"100621922","acute-effect-of-graded-motor-imagery-on-ankle-rehabilitation-a-pilot-study-100621922","NCT07376915","Acute Effect of Graded Motor Imagery on Ankle Rehabilitation: A Pilot Study","The Acute Effect of Graded Motor Imagery-Based Mental Preparation on Ankle Rehabilitation: A Pilot Clinical Study","Inclusion Criteria:\n\n* Aged between 18 and 40 years.\n* Diagnosed with chronic ankle instability (CAIT ≤ 24).\n* History of an acute ankle sprain occurring more than 3 months prior to enrollment.\n* Has not received ankle rehabilitation treatment.\n* Voluntarily participated in this study\n\nExclusion Criteria:\n\n* Vestibular or neurological disorders\n* Other lower extremity injuries\n* History of surgery","40 Years",{"count":339,"type":23},[26],"The primary aim of this study is to evaluate the immediate and short-term effects of the Graded Motor Imagery (GMI) method on individuals with chronic ankle instability (CAI). In this context, the effects of the Graded Motor Imagery intervention on pain level, muscle stiffness, muscle strength, functional performance, and subjective instability level will be investigated. Additionally, these effects will be comparatively analyzed with an age- and sex-matched control group consisting of healthy individuals.",[417,72],"Ankle Instability",{"date":396,"type":52},{"date":352,"type":52},{"date":421,"type":23},"2026-06-09",{"name":423,"class":59},"Istanbul University - Cerrahpasa",{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":17,"sex":18,"minAge":363,"maxAge":430,"enrollmentInfo":431,"targetDuration":4,"studyType":24,"phases":433,"briefSummary":435,"conditions":436,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":90},"100523662","early-phase-1-pet-imaging-evaluation-of-11csy08-100523662","NCT06098612","PET Imaging Evaluation of [11C]SY08","Inclusion Criteria:\n\n* General Inclusion criteria, all subjects must:\n\n  1. Age 50-80\n  2. Be able to provide written informed consent or assent\n  3. Be able to read, speak and understand English (The investigators do not have the resources necessary to properly study non-English speaking patients in this study, given that translation and validation of the assessment tools would be necessary)\n  4. Be willing and able to participate in one PET\u002FMRI scanning session\n\nAdditional Inclusion criteria for PD patients, subjects must:\n\n1. Have an existing diagnosis of idiopathic PD, using consensus criteria\n2. Stable medications for at least 30 days\n3. Hoehn and Yahr stage I-IV\n4. A study partner who can answer questions pertaining to daily functioning\n\nAdditional Inclusion criteria for MSA patients, subjects must:\n\n1. Have an existing diagnosis of MSA, using consensus criteria\n2. Stable medications for at least 30 days\n3. MSAp or MSAc\n4. A study partner who can answer questions pertaining to daily functioning\n\nAdditional Inclusion criteria for DLB patients, subjects must:\n\n1. Have an existing diagnosis of probable DLB, using consensus criteria\n2. Stable medications for at least 30 days\n3. Clinical Dementia Rating Scale (CDR) \\\u003C 0.5\n4. A study partner who can answer questions pertaining to daily functioning\n\nExclusion Criteria:\n\n* General Exclusion Criteria (All Subjects)\n\n  1. History of vascular risk factors (e.g. hypertension, hyperlipidemia), if not well-controlled\n  2. Major psychiatric disease (e.g.schizophrenia)\n  3. History of stroke\n  4. Focal brain lesions on MRI scans\n  5. History of other major illnesses including, but not limited to, major kidney or liver problems or significant neurological illness\n  6. Recent surgery that is deemed major by our reviewing physician or nurse practitioner within the past 6 months\n  7. History of head trauma (as defined as having any insults to the brain that may have resulted from an external mechanical force, such as rapid acceleration or deceleration, impact, blast waves, or penetration by a projectile)\n  8. Impaired elimination (as defined as having problems with urination) unless being managed\n  9. Past or present diagnosis of bipolar disorder or other Axis I diagnosis, (treated depression is allowed)\n  10. Any present substance abuse including drug\u002Falcohol abuse\n  11. Inability to lie flat on camera bed for up to 90 min\n  12. Pregnancy or breastfeeding\n  13. Metallic foreign bodies that would be affected by the MRI magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan\n  14. Recent exposure to radiation (i.e., PET from other research) that, when combined with this study, would be above the allowable limits (50 milliSieverts)\n\nGeneral MR and PET safety exclusion criteria listed below\n\n1. Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, steel implants, ferromagnetic objects such as jewelry or metal clips in clothing\n2. Electrical implants such as cardiac pacemakers or perfusion pumps\n3. Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest\n4. Is unable to lie comfortably on a bed inside a PET camera with their head in the field of view for 60 to 90 minutes as assessed by physical examination and medical history (e.g. back pain, arthritis)\n5. Pregnancy: A negative serum pregnancy test is required on the day of the PET procedure in women of child bearing potential\n6. Body weight of \\> 300 lbs (weight limit of the MRI table)\n7. Breast feeding mothers\n\nExclusion Criteria for Subjects Undergoing Blood Draws Through an Arterial Line During PET Scan\n\n1. An abnormal result on the modified Allen's test on both hands\n2. Raynaud syndrome\n3. Bleeding disorder\n4. Use of anticoagulants such as Coumadin, Plavix or Lovenox\n5. An allergy to Lidocaine","80 Years",{"count":432,"type":23},40,[434],"EARLY_PHASE1","The overall goal of the proposed research is to evaluate the use of \\[11C\\]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls.\n\nThe purpose of this study is to evaluate the use of \\[11C\\]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls. The specific aims of the current study are:\n\n1. To determine brain uptake, distribution, and kinetics of \\[11C\\]SY08 in healthy individuals.\n2. To determine brain uptake, distribution, and kinetics of \\[11C\\]SY08 in patients with alpha synuclein aggregates in the brain, including PD, DLB and MSA.\n3. To determine human dosimetry of \\[11C\\]SY08 in healthy individuals\n\nAn intravenous bolus injection of \\[11C\\]SY08 will be administered per subject for brain PET imaging.",[437,438,369,72],"Parkinson's Disease","Multiple System Atrophy","2025-12-18",{"date":441,"type":52},"2025-12-24",{"date":443,"type":52},"2024-05-01",{"date":445,"type":23},"2027-11",{"name":447,"class":59},"Massachusetts General Hospital",{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":17,"sex":18,"minAge":97,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":455,"conditions":456,"keywords":459,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":90},"100614168","physical-and-psychosocial-parameters-in-takayasu-arteritis-and-behets-disease-a-comparative-study-with-healthy-controls-100614168","NCT07276087","Physical and Psychosocial Parameters in Takayasu Arteritis and Behçet's Disease: A Comparative Study With Healthy Controls","Inclusion Criteria:\n\nInclusion Criteria (Takayasu Arteritis Group):\n\n* Age 18 years or older.\n* Diagnosis of Takayasu arteritis according to the American College of Rheumatology (ACR) classification criteria.\n* Voluntary participation with written informed consent.\n\nInclusion Criteria (Behçet's Disease Group):\n\n* Age 18 years or older.\n* Diagnosis of Behçet's disease according to the International Study Group for Behçet's Disease criteria.\n* Voluntary participation with written informed consent.\n\nInclusion Criteria (Healthy Control Group):\n\n* Age 18 years or older.\n* No history of systemic, rheumatologic, or chronic inflammatory disease.\n* Voluntary participation with written informed consent.\n\nExclusion Criteria:\n\nExclusion Criteria (Patient Groups - Takayasu Arteritis and Behçet's Disease):\n\n* Pregnancy.\n* Presence of psychiatric disorder or ongoing psychiatric treatment.\n* Cognitive impairment that may interfere with participation.\n* Presence of neurological disease (e.g., hemiplegia, Parkinson's disease, multiple sclerosis, vertigo, epilepsy, etc.).\n* History of any surgical operation within the past year.\n* Coexisting rheumatic disease other than Takayasu arteritis or Behçet's disease.\n\nExclusion Criteria (Healthy Control Group):\n\n* Pregnancy.\n* Presence of psychiatric disorder or ongoing psychiatric treatment.\n* Cognitive impairment that may interfere with participation.\n* Presence of neurological disease (e.g., hemiplegia, Parkinson's disease, multiple sclerosis, vertigo, epilepsy, etc.).\n* History of any surgical operation within the past year.\n* History of rheumatologic or chronic inflammatory disease.",{"count":152,"type":23},"Systemic vasculitis refers to a group of rare diseases characterized by inflammation of blood vessel walls, which may cause ischemia and structural damage in various organs. Among large-vessel vasculitides, Takayasu arteritis primarily affects the aorta and its main branches, whereas Behçet's disease is a variable vessel vasculitis involving arteries and veins of all sizes. Both conditions can lead to multisystemic involvement and significantly impact physical and psychosocial health.\n\nThis observational, case-control study aims to compare multiple physical and psychosocial parameters among individuals with Takayasu arteritis, Behçet's disease, and healthy controls. Assessments will include respiratory and peripheral muscle strength, functional status, exercise capacity, body composition, quality of life, illness perception, and psychological well-being. Measurements will be conducted using standardized clinical tests (such as maximal inspiratory and expiratory pressures, handgrip and limb strength dynamometry, squat test, and six-minute walk test) and validated questionnaires (Health Assessment Questionnaire (HAQ), the Short Form-36 Health Survey (SF-36), the EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L), and the Visual Analogue Scale (VAS)).\n\nThe study seeks to identify differences between groups and provide a comprehensive understanding of how systemic inflammation in Takayasu arteritis and Behçet's disease affects physical performance, quality of life, and psychosocial health. These findings may help guide physiotherapy, rehabilitation, and multidisciplinary management strategies for patients with systemic vasculitis.",[457,458,72],"Takayasu Arteritis","Behçet's Disease",[460,461,462,463],"Takayasu arteritis","Behçet's disease","Systemic vasculitis","Muscle strength","2025-12-09",{"date":466,"type":52},"2025-12-10",{"date":468,"type":52},"2025-09-11",{"date":470,"type":23},"2026-01-30",{"name":472,"class":59},"ÖZLEM NUR TOK YAMAN",{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":477,"acronym":478,"eligibilityCriteria":479,"healthyVolunteers":17,"sex":18,"minAge":97,"maxAge":184,"enrollmentInfo":480,"targetDuration":4,"studyType":24,"phases":482,"briefSummary":483,"conditions":484,"keywords":486,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":90},"100612088","impact-of-epilepsy-on-the-brainstem-adenosine-pathway-and-its-relation-with-arousal-and-respiratory-reactivity-100612088","NCT07249034","Impact of Epilepsy on the Brainstem Adenosine Pathway and Its Relation With Arousal and Respiratory Reactivity","BRAVE","Inclusion Criteria:\n\n* For patients\n\n  1. Written informed consent obtained from study subject and ability for study subject to comply with the requirements of the study\n  2. Aged 18 to 55 years old\n  3. Diagnosis of focal epilepsy or of idiopathic generalized epilepsy, as defined by the International League Against Epilepsy\n  4. Diagnosis of refractory epilepsy, as defined by the International League Against Epilepsy\n  5. Patients with ≥3 focal to bilateral tonic-clonic seizure (FBTCS) during the past 18 months\n  6. For women of childbearing potential, use effective contraception during study participation\n* For healthy volunteers\n\n  1. Written informed consent obtained from study subject and ability for study subject to comply with the requirements of the study\n  2. Aged 18 to 55 years old\n  3. For women of childbearing potential, use effective contraception during study participation\n\nExclusion Criteria:\n\n* For patients\n\n  1. Ongoing or chronic respiratory and\u002For cardiac insufficiency\n  2. Obstructive sleep-apnea syndrome\n  3. Ongoing treatment with selective serotonin reuptake inhibitor\n  4. MRI contra-indication (presence of metallic elements, claustrophobia)\n  5. Patient treated with vagal nerve stimulation or deep brain stimulation\n  6. Pregnant women, women in laboror breastfeeding women, based on declarations at V0\n  7. Persons under psychiatric care\n  8. Persons deprived of their liberty by a judicial or administrative decision\n  9. Adults subject to a legal protection measure (guardianship, curatorship)\n  10. Persons not affiliated to a social security scheme or beneficiaries of a similar scheme\n  11. Positive urine pregnancy test at V2, if applicable\n  12. Hypersensitivity to \\[18F\\]-CPFPX\n* For healthy volunteers\n\n  1. History of epilepsy\n  2. Ongoing or chronic respiratory and\u002For cardiac insufficiency\n  3. Obstructive sleep-apnea syndrome\n  4. Ongoing treatment with selective serotonin reuptake inhibitor\n  5. MRI contra-indication (presence of metallic elements, claustrophobia)\n  6. Pregnant women, women in labor or breastfeeding women, based on declarations at V0\n  7. Persons under psychiatric care\n  8. Persons deprived of their liberty by a judicial or administrative decision\n  9. Adults subject to a legal protection measure (guardianship, curatorship)\n  10. Persons not affiliated to a social security scheme or beneficiaries of a similar scheme\n  11. Positive urine pregnancy test at V2, if applicable\n  12. Hypersensitivity to \\[18F\\]-CPFPX",{"count":481,"type":23},50,[26],"Despite the continuous development of new antiseizure medications over the past 25 years, 30% of patients with epilepsy suffer from drug-resistant seizures and are at risk of epilepsy-related complications, like cognitive dysfunctions, sleep-disordered breathing or Sudden and Unexpected Death in Epilepsy (SUDEP). SUDEP typically occurs during sleep, after a nocturnal seizure, and primarily results from a postictal central respiratory dysfunction in patients with generalized convulsive seizure (GCS), suggesting that interaction between respiratory dysfunction and sleep state may play a role in its pathophysiology.\n\nPost-mortem data in SUDEP patients showed alteration of neuronal populations involved in respiratory control in the medulla. Accordingly, pharmacologic strategies aimed at reducing the severity of postictal respiratory dysfunction has appeared as one of the most promising way to prevent SUDEP. However, no encouraging result has hitherto been reported.\n\nInterconnections between the complex network that regulates arousal and sleep and the respiratory network are numerous. They primarily include the relation between chemosensitive regulation and arousal system to ensure asphyxia-induced arousal (i.e. arousal to elevated CO2), especially through serotonin (5HT)-dependent connections in brain stem. The link between alterations of the brainstem networks involved in arousal regulation and respiratory dysfunction has not been characterized in patients with epilepsy yet.\n\nLike 5HT, adenosine is deeply implicated in the regulation of sleep and central respiratory control.\n\nSeizures transiently increase adenosine extracellular levels. Adenosine physiological effects in the brain are mediated through the activation of two types of Adenosine receptors (ARs), A1Rs and A2ARs. Extracellular adenosine promotes sleep via A1R-dependant inhibition of glutamatergic neurons in the basal forebrain, but also via A2AR-dependant activation of neurons in the nucleus accumbens. Respiration is also inhibited by A1R and A2AR. Most importantly, it has been shown that drug-resistant epilepsy is associated with long-term alterations of ARs cortical expression. However, whether or not a similar epilepsy-related plasticity of ARs occurs in the brainstem and may participate to chronic arousal and respiratory dysfunction in epilepsy has never been investigated.\n\nConsidering the tight interplay between central respiratory control, arousal regulation and brainstem adenosine, the main hypothesis of the BRAVE study is that epilepsy might result in alterations of the distribution of A1Rs in the brainstem structures involved in respiratory regulation and\u002For arousal control, especially in the brainstem structures involved in respiratory regulation under hypercapnic condition.\n\nThe study combines clinical respiratory characterization, morphological, functional and metabolic imaging, using the hybrid simultaneous 3T MRI-PET scanner (Siemens Biograph mMR) of the CERMEP. Combining PET with anatomical and functional MR imaging enables non-invasively in vivo mapping of receptor binding and functional neuronal assessment of a physiological task in the entire brain with high spatial resolution.\n\nInvestigators already performed fMRI study of respiratory centers, showing number of functional changes in brainstem regions participating to the central control of respiration, including reduced activation during breath-holding fMRI, in patients with epilepsy. The BRAVE study will use the same respiratory paradigm as the one used in this past study.\n\nPET imaging will be focused on A1R, using \\[18F\\]CPFPX, a selective A1R antagonist.",[156,485,72],"Drug-resistant Focal Epilepsy",[156,487,488,164,489],"adenosine pathway","respiratory reactivity","[18F]CPFPX","2025-11-21",{"date":492,"type":52},"2025-11-25",{"date":494,"type":23},"2026-01-01",{"date":496,"type":23},"2028-03-01",{"name":175,"class":59},{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":4,"eligibilityCriteria":504,"healthyVolunteers":17,"sex":18,"minAge":505,"maxAge":98,"enrollmentInfo":506,"targetDuration":4,"studyType":24,"phases":508,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":90},"100441247","early-phase-1-ha35-acute-alcohol-study-100441247","NCT05025865","HA35 Acute Alcohol Study","Mechanisms by Which HA35 Regulates Muscle Protein Homeostasis in Healthy Controls","Inclusion Criteria:\n\n* Alcohol consumption of less than 7 drinks per week for women and less than 14 drinks per week for men\n* Ability to understand and willingness to provide written consent\n\nExclusion Criteria:\n\n* Any known chronic illness including but not limited to cancer (except non-melanoma skin cancer)\n* Poorly controlled diabetes (Hemoglobin A1c \\>9.5 g\u002Fdl)\n* Untreated hyper\u002Fhypothyroidism\n* Uncontrolled hypertension or hypercholesterolemia\n* End-stage renal disease\n* Liver disease of any etiology\n* Coronary artery disease or stroke\n* Active intravenous drug use\n* History of gastric bypass\n* Medications known to alter muscle protein synthesis (systemic corticosteroids, tamoxifen, high dose estrogen, testosterone, or anabolic steroids)\n* Pregnancy\n* Past alcohol use disorder\n* Abnormal clotting factors","21 Years",{"count":507,"type":23},24,[434],"Eligible subjects will be asked to take a placebo\u002Ftreatment capsule for a total of 3 days and then participate in a study visit on the fourth day. This study visit will include a medical exam, clinical labs, questionnaires, body composition measurements, and urine and stool collections. Additionally, participants will consume a sugar cocktail to measure their gut permeability, participate in an acute ethanol challenge, and undergo two muscle biopsies. The study will take approximately 3-4 hours and a designated driver will need to drive the participant home. On the fifth day, you will be asked to return to drop of the 24-hour urine collection.",[72],"2025-11-14",{"date":513,"type":52},"2025-11-17",{"date":515,"type":52},"2022-02-01",{"date":517,"type":23},"2027-10-01",{"name":519,"class":59},"The Cleveland Clinic",{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":524,"acronym":525,"eligibilityCriteria":526,"healthyVolunteers":17,"sex":18,"minAge":97,"maxAge":98,"enrollmentInfo":527,"targetDuration":4,"studyType":24,"phases":529,"briefSummary":530,"conditions":531,"keywords":532,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":90},"100536354","cold-and-heat-investigation-to-lower-levels-of-depression-100536354","NCT06263738","Cold and Heat Investigation to Lower Levels of Depression","CHILL'D","Inclusion Criteria:\n\n* Individuals who currently meet study criteria for depression or individuals who do not currently meet criteria for depression\n* English or Spanish speaking (able to provide informed consent and complete questionnaires in one of these languages)\n* Able and willing to adhere to trial requirements, including attending all trial visits, preparatory and follow-up sessions, and completing all trial evaluations.\n\nExclusion Criteria:\n\n* Previous adverse reaction to hypothermia, hyperthermia and\u002For infrared exposure\n* Use of any medication that may impact thermoregulatory capacity.\n* Pregnancy, active lactation, or intention to become pregnant during the study period.\n* Endorses current active suicidal ideation with a plan or made a suicide attempt in the prior 6 months.",{"count":528,"type":23},162,[26],"This study will recruit 112 medically healthy adults (aged 18-65) currently experiencing depressive symptoms to be randomized to receive either a single Whole Body Hyperthermia (heat therapy) treatment or a Whole Body Hyperthermia treatment followed by a cold water plunge. Participants will complete a baseline assessment of their depressive symptoms as well as 1-week and 2-week post-treatment followup assessments.",[251,249,30],[251,249,533,534,535,536,537],"Mental Health","Integrative Health","Hyperthermia","Sauna","Cold Plunge","2025-11-11",{"date":540,"type":52},"2025-11-13",{"date":542,"type":52},"2024-05-14",{"date":544,"type":23},"2027-04-01",{"name":546,"class":59},"Barry Sandler",{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":17,"sex":18,"minAge":97,"maxAge":98,"enrollmentInfo":554,"targetDuration":4,"studyType":24,"phases":556,"briefSummary":557,"conditions":558,"keywords":559,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":90},"100600627","dose-dependent-effects-of-low-intensity-focused-ultrasound-100600627","NCT07099950","Dose-Dependent Effects of Low-Intensity Focused Ultrasound","Dose-Dependent Functional Connectivity Effects of Low-Intensity Focused Ultrasound Applied to Deep White Matter Tracts in Humans","Inclusion Criteria:\n\n* Age 18 to 65 years.\n* Body mass index 17-38 kg\u002Fm2.\n* Fluent English speaker, capable of providing written informed consent.\n* Overall Anxiety Severity and Impairment Scale \\\u003C8 and Patient Health Questionnaire-9 \\\u003C10\n* A person of childbearing potential must have a negative urine pregnancy test at screening\n* Consent that random observations of pathology are possible (e.g., brain abnormality seen during imaging).\n\nExclusion Criteria:\n\n* Inability to provide informed consent including medical, psychiatric, or other conditions that restrict the patient's following abilities: to interpret the study information, to give informed consent, to adhere to the rules of the protocol, or complete the study.\n* No telephone or easy access to telephone\n* Has active suicidal ideation (as measured by Suicide-Risk-Assessment-C-SSRS \"Yes\" answers to items 3, 4, or 5 Suicidal Ideation-Past 1 month section, or any \"Yes\" answer to any of the items of Suicidal Behavior-Past 3 months section), or any suicide attempt in the last 3 months\n* Has positive test result(s) for alcohol of abuse (including methadone, opiates, cocaine, amphetamine\u002Fmethamphetamine and ecstasy), or substance use disorder including alcohol, stimulants, sedatives, and cannabis exceeding mild severity in the last 6 months\n* Has a lifetime APA Diagnostic and Statistical Manual of Mental Disorders (DSM)-5th edition including major depression, generalized anxiety disorder, specific phobias, panic disorder, post-traumatic stress disorder, schizophrenia spectrum and other psychotic disorders, obsessive-compulsive disorder, or bipolar disorder.\n* Benzodiazepines or anticonvulsants in the 7 days prior to participation.\n* MRI contradictions as detected by the MRI Safety Screen including claustrophobia and unwillingness and inability to complete scans (e.g., unable to lie on one's back for 60 mins.\n* Clinical history of relevant structural pathology of the central nervous system, including Parkinson's disease, multiple sclerosis, and brain malignant neoplasia.\n* History of unstable liver or renal insufficiency; significant and unstable cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, hematological, rheumatological, or metabolic disturbance; or any other condition that, in the opinion of the investigator, would make participation not be in the best interest (e.g., compromise the well-being) of the subject or that could prevent, limit or confound the protocol-specified assessments, including uncontrolled diabetes mellitus (ss evidenced by fasting glycemia ≥ 120 mg\u002FdL or hemoglobin A1c ≥ 6.5%) or hypertension (as evidenced by two consecutive readings ≥ 140\u002F90 mmHg) to ensure medical stability throughout this longitudinal study.\n* Moderate-to-severe traumatic brain injury or any other clinical neurocognitive disorder.\n* Clinical history of at least minor neurocognitive disorder of any origin.\n* Prescription of a medication outside of the accepted range, as determined by best clinical practices and current research.\n* Use of any psychotropic medication.\n* Unwillingness or inability to complete any major aspects of the study protocol.\n* Prior neurosurgery.\n* Non-correctable vision or hearing.",{"count":555,"type":23},66,[26],"Low-intensity focused ultrasound (LIFU) has emerged as a tool to modulate the activity of deep brain structures noninvasively and reversibly, with anatomical precision. Following the results of a pilot study in which the investigators observed target engagement when LIFU was applied to the anterior limb of the internal capsule, the investigators now propose to determine the dose-response relationships of LIFU when applied to deep white matter tracts of the human brain. The investigators hope a successful study will be rapidly translatable into clinical trials seeking to understand mechanistic brain circuit-symptom relationships in major psychiatric disorders.",[72],[560,561],"Low-Intensity Focused Ultrasound","Functional Connectivity","2025-10-14",{"date":564,"type":52},"2025-10-16",{"date":566,"type":52},"2025-04-22",{"date":568,"type":23},"2026-12",{"name":229,"class":59},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":17,"sex":18,"minAge":97,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":579,"conditions":580,"keywords":591,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":598,"leadSponsor":600,"locationsCount":4},"100607417","mass-spectrometry-based-immune-profiling-in-autoimmune-diseases-100607417","NCT07188285","Mass Spectrometry-based Immune Profiling in Autoimmune Diseases","Mass Spectrometry-based Immune Profiling in Peripheral Blood of Autoimmune Diseases","Inclusion Criteria:\n\n1. Male or female, and aged 18-70 at the time of screening interview (inclusive).\n2. The diagnosis of each disease meets the following standards - Systemic lupus erythematosus: 1997 ACR lupus classification standard\n\n   * Behcet's disease: 2014 ICBD Behcet's disease classification standard\n   * ANCA-associated vasculitis: 1990 American College of Rheumatology Classification Standard\n   * Rheumatoid arthritis: 1987 ARA classification standard\n   * Ankylosing spondylitis: new york standard revised in 1984\n   * Sjogren's syndrome: 2016 ACR\u002FEULAR Sjogren's syndrome classification standard\n   * Inflammatory myopathy: Bohan recommended criteria in 1977\n   * Systemic sclerosis: SSc standard formulated by American Rheumatology Association in 1980.\n   * Psoriatic arthritis: CASPAR standard in 2006\n   * Gouty arthritis: 1997 ACR gout classification standard\n3. Disease activity status, each disease should meet the disease activity index;\n4. Glucocorticoid (≤1mg\u002Fkg\u002Fd prednisone or other hormones with equivalent dose) was used before joining the group, and DMARDs (such as methotrexate, hydroxychloroquine, azathioprine, mycophenolate mofetil, leflunomide, cyclosporine, etc.) were allowed;\n5. When participating in the trial, the patient must be informed in writing and hope that the patient can abide by the requirements of the research follow-up plan and other protocols.\n\n   Exclusion Criteria:\n\n1\\. Use IVIg or cyclophosphamide within 1.2 months, use other biological agents (infliximab, adalimumab, etanercept, anakinra, etc.) within 3 months, and use rituximab within 6 months; 2.1 months after receiving high-dose glucocorticoid (\\> 1 mg\u002Fkg\u002Fd). 3. Serious complications: including heart failure (≥ NYHA III), renal insufficiency (creatinine clearance rate ≤30 ml\u002Fmin) and hepatic insufficiency (serum ALT or AST is greater than three times the normal upper limit, or total bilirubin is greater than the normal upper limit).\n\n4\\. Other serious, progressive or uncontrollable hematological, gastrointestinal, endocrine, lung, heart, nerve or brain diseases (including demyelinating diseases, such as multiple sclerosis).\n\n5\\. Suffering from serious infection (including but not limited to hepatitis, pneumonia, bacteremia, pyelonephritis, EB virus, tuberculosis infection), or being hospitalized due to infection, or using intravenous antibiotics to treat infection 2 months before the first dose of treatment.\n\n6\\. Chest imaging showed abnormalities of malignant tumor or current active infection (including tuberculosis) within 3 months before enrollment.\n\n7\\. Infected with HIV(HIV antibody positive serology) or hepatitis C (Hep C antibody positive serology). If the serum is positive, it is recommended to consult a doctor with expertise in treating HIV or hepatitis C virus infection.\n\n8\\. Any known malignant tumor or history of malignant tumor in the past 5 years. 9. Received any vaccination within 3 months before joining the group.",{"count":578,"type":23},500,"Based on mass spectrometry flow method, this study analyzed the typing of new T, B, NK and DC cell subsets in peripheral blood of common autoimmune diseases and their correlation with disease activity, aiming at establishing an early screening and diagnosis model of autoimmune diseases.",[581,582,583,584,585,586,587,588,589,590,72],"Systemic Lupus Erthematosus","Sjogren's Syndrome","Inflammatory Myopathies","Systemic Sclerosis (SSc)","Vasculitis","Rheumatoid Arthritis (RA)","Ankylosing Spondylitis","Osteoarthritis","Gouty Arthritis (GA)","Psoriatic Arthritis (PsA)",[592,593],"autoimmune diseases","mass spectrometry","2025-09-16",{"date":596,"type":52},"2025-09-23",{"date":594,"type":23},{"date":599,"type":23},"2026-09-30",{"name":601,"class":59},"Peking University People's Hospital",{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":606,"acronym":4,"eligibilityCriteria":607,"healthyVolunteers":17,"sex":18,"minAge":505,"maxAge":19,"enrollmentInfo":608,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":610,"conditions":611,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":90},"100417877","aberrant-synaptic-plasticity-in-cocaine-use-disorder-a-11c-ucb-j-pet-study-100417877","NCT04721418","Aberrant Synaptic Plasticity in Cocaine Use Disorder: A 11C-UCB-J PET Study","Inclusion Criteria:\n\n* Age 21-60 years\n* Physically healthy by medical history, physical, neurological, ECG and laboratory examinations\n* For females, a negative serum pregnancy test\n* For CUD: DSM-5 criteria for Cocaine Use Disorder and positive urine toxicology showing recent use\n* For HC: Negative urine toxicology\n\nExclusion Criteria:\n\n* DSM-5 criteria for other substance use disorders (e.g., alcohol, opiates, sedative hypnotics), except for nicotine\n* A primary DSM-5 Axis I major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depression, etc.) as determined by the Structured Clinical Interview for DSM-5 (SCID-5)\n* A history of significant and\u002For uncontrolled medical or neurological illness\n* Current use of psychotropic and\u002For potentially psychoactive prescription medications\n* Medical contraindications to MRI procedure",{"count":609,"type":23},80,"The purpose of this research study is to measure synaptic density in the brain comparing individuals with cocaine use disorder to healthy controls.",[612,72],"Cocaine Use Disorder","2025-09-09",{"date":468,"type":52},{"date":616,"type":52},"2021-07-20",{"date":618,"type":23},"2026-06",{"name":620,"class":59},"Yale University",{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":625,"acronym":626,"eligibilityCriteria":627,"healthyVolunteers":17,"sex":18,"minAge":97,"maxAge":4,"enrollmentInfo":628,"targetDuration":4,"studyType":24,"phases":630,"briefSummary":631,"conditions":632,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":4},"100600667","metabolic-characterization-of-alzheimers-disease-and-frontotemporal-dementia-by-23na-mri-and-fdg-pet-100600667","NCT07100470","Metabolic Characterization of Alzheimer's Disease and Frontotemporal Dementia by 23Na-MRI and FDG-PET","MetaAD_FTD","Inclusion Criteria:\n\n* Patients with Alzheimer's disease\n\n  * CDR (Clinical Dementia Rating Scale) = 0.5 or 1\n  * Progressive amnestic syndrome, associated or not with other cognitive impairments\n  * Biological criteria: CSF biomarkers suggestive of AD-continuum (Jack et al., 2018)\n* Patients with FTD\n\n  * Modifications of the personality and the social conducts in the foreground (behavioral variant) (Rascovsky et al., 2011)\n  * Primary progressive aphasia (Gorno-Tempini et al., 2011):\n\n    * Effortful, agrammatic speech plus at least one of: a) impaired grammar\u002Fsentence comprehension with relatively preserved single word comprehension, or b) groping, distorted speech production (apraxia of speech)\n    * Semantic language disorders\n  * Compatible brain imaging: profile of atrophy and\u002For hypometabolism on FDG-PET (or hypoperfusion on SPECT) compatible with the diagnosis of FTD and\u002For absence of atypia\n  * Biological criteria: No AD profile on CSF biomarkers if available; if CSF not available: diagnosis based on clinical criteria left to the judgment of the investigators\n* Cognitively healthy controls\n\n  * Absence of known psychiatric disorder\n  * Score on the Folstein Mini-Mental State Examination (MMSE \\> or = 27) with no more than one word missing\n  * Normal neuropsychological assessment for the age and the educational level, particularly Scores on the Free and Cued Selective Reminding Test (FCSRT) of \\>25 for free recall and \\>44 for total recall.\n\nExclusion Criteria:\n\n* Subject with an evolving and\u002For badly checked psychiatric pathology (left to the judgment of the investigator).\n* Subject with a grave, severe or unstable pathology (left to the judgment of the investigator) the nature of which can interfere with the variables of evaluation.\n* Epileptic subjects, with poor tolerance to MRI (1.5T, 3T or 7T),\n* Subject presenting contraindications to the MRI such as Pacemaker or stimulating neurosensory or implantable defibrillator, cochlear implants, eye or cerebral ferromagnetic foreign bodies close to nervous structures, metallic prostheses, neurosurgical ventriculoperitoneal shunt valves\n* Known or supposed histories (\\\u003C or = 5 years) of severe alcoholism or misuse of drugs\n* Vascular, inflammatory or expansive, lesion visible on the MRI which can interfere with the criteria of diagnosis.\n* No health insurance\n* Agitation of the patient: not cooperative or agitated patients, claustrophobic subjects",{"count":629,"type":23},55,[26],"Alzheimer's disease (AD) and frontotemporal dementia (FTD) are the most common forms of neurodegenerative dementia. However, their differential and timely diagnosis can be challenging for clinicians, therefore often closing the door for an early and possibly successful treatment before irreversible cerebral damage occurs. Hence, treatment options often become available only at a late point in time. In Alzheimer's disease, early neuroimaging markers are glucose hypometabolism and Amyloid-\u002FTau-depositions (PET). Recent findings from sodium magnetic resonance imaging (23Na-MRI) point to brain tissue sodium concentration as a metabolic marker of AD progression. Sodium is crucial for neurotransmission and cellular homeostasis maintained by the cellular Na+\u002FK+-ATPase, depending on Adenosine-Triphosphate as energy source from the mitochondrial respiratory chain, also interacting with tau and amyloid. In this project, we aim to characterize disease-specific metabolic patterns in AD vs. FTD by performing 23Na-MRI in association to FDG-PET to support early positive and differential diagnosis and therapeutic follow-up in both diseases in association to clinical parameters such as CSF\u002Fblood markers and neuropsychological assessment. Assessment of 7T MRI including 23Na-MRI, 31P-MRS and 1H-MRI is planned with analysis of results in association with FDG-PET, Amyloid- and Tau-PET, blood and CSF biomarkers as well as neuropsychological and clinical assessment.",[633,634,72],"FTD","AD","2025-07-28",{"date":637,"type":52},"2025-08-03",{"date":639,"type":23},"2025-10-01",{"date":641,"type":23},"2029-03-01",{"name":643,"class":59},"Centre Hospitalier St Anne",{"id":645,"slug":646,"hasResults":12,"nctId":647,"briefTitle":648,"officialTitle":649,"acronym":4,"eligibilityCriteria":650,"healthyVolunteers":17,"sex":18,"minAge":651,"maxAge":309,"enrollmentInfo":652,"targetDuration":4,"studyType":24,"phases":654,"briefSummary":655,"conditions":656,"keywords":658,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":668,"lastUpdatePostDateStruct":669,"startDateStruct":671,"completionDateStruct":673,"leadSponsor":675,"locationsCount":90},"100557786","mechanisms-of-response-to-therapeutic-intervention-in-clinical-high-risk-chr-for-psychosis-100557786","NCT06542640","Mechanisms of Response to Therapeutic Intervention in Clinical High Risk (CHR) for Psychosis","Identifying Mechanisms of Response to Therapeutic Intervention in Clinical High Risk (CHR) for Psychosis: a Bridge to Treatment","Inclusion Criteria:\n\nClinical High Risk (CHR):\n\n1. Male or female between 15 and 35 years old.\n2. Can understand and sign an informed consent (or assent for minors) document.\n3. Must meet the substance use criteria:\n\n   1. No Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) Alcohol or Drug Dependence in the past 3 months;\n   2. No use on the day of assessment, clearly not intoxicated or hung-over.\n4. Must meet diagnostic criteria for a prodromal syndrome. If under the age of 19 and meet diagnostic criteria for Schizotypal Personality Disorder or meet the diagnostic criteria called the Criteria for Prodromal Syndromes (COPS), which are operationalized as follows (a-c below):\n\n   1. Genetic Risk and Deterioration Syndrome (GRDS): First degree biological relative with psychosis or subject with Schizotypal Personality Disorder and a 30% drop in Global Assessment of Functioning (GAF) score compared to one year ago, sustained over the past month.\n   2. Attenuated Positive Symptoms Syndrome (APSS): Severity rating of moderate (rating of 3), moderately severe (4) or severe but not psychotic (5) on any one of the five Symptoms of Psychotic Disorders (SOPS) positive symptoms; symptom occurs at or above moderate severity level at an average frequency of at least once per week in the past month; symptom must have begun in the past year or currently rates at least one scale point higher than rated 12 months previously.\n   3. Brief Intermittent Psychotic Syndrome (BIPS): Severity rating of psychotic intensity (6) on any of the 5 SOPS positive symptoms; symptom is present at least several minutes per day at a frequency of at least once per month; symptom(s) must have reached a psychotic intensity in the past 3 months; symptom is not seriously disorganizing or dangerous; symptom(s) do not last for more than 1 hour\u002Fday at an average frequency of 4 days\u002Fweek over 1 month.\n5. . Participant may be remitted from the CHR syndrome or may have converted to a full psychotic disorder since study entry and either is acceptable - they remain eligible to participate in follow-up procedures.\n\nExclusion Criteria:\n\n1. Meet criteria for current or lifetime Axis I psychotic disorder, including affective psychoses and psychosis Not Otherwise Specified (NOS) at the baseline assessment\n2. Impaired intellectual functioning (i.e., Intelligence Quotient (IQ)\\\u003C70) at baseline.\n3. Past history of or current clinically significant central nervous system disorder that may contribute to prodromal symptoms or confound their assessment.\n4. Traumatic Brain Injury that is rated as 7 or above on the Traumatic Brain Injury screening instrument (signifying a significant brain injury with persistent sequelae) or current concussion that interferes with any assessment measures.\n5. Diagnostic prodromal symptoms that are clearly caused by one or more other psychiatric disorders, including substance use disorders, in the judgment of the evaluating clinician. Other non-psychotic Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) disorders will not be exclusionary (e.g., substance abuse disorder, major depression, anxiety disorders, personality disorders), as long as the disorder does not account for the diagnosis of prodromal symptoms.\n\nHealthy Controls (HC):\n\n1. Must meet subject inclusion criteria 1-2 and exclusion criteria 1-5. Must not meet criteria for any prodromal syndrome, any current or past psychotic disorder or Cluster A personality disorder diagnosis and must not be receiving any current treatment with psychotropic medication at the baseline assessment.\n2. Must not have a family history (in first-degree relatives) of schizophrenia, schizoaffective disorder, schizotypal personality disorder, or any other disorder involving psychotic symptoms.","15 Years",{"count":653,"type":23},300,[26],"This study, \"Psychobiological Follow-up Study of Transition from Prodrome to Early Psychosis\", will be conducted in collaboration with the Shanghai Mental Health Center (SMHC) and several data processing sites in the United States. The current study builds on findings from the investigator's previous work that identified several biomarkers in participants at clinical high risk (CHR) for psychosis that may be related to clinical outcomes such as the development of psychosis. This study responds to the critical need to understand links between biomarkers (could be clinical, cognitive, biological or other abnormalities) and later clinical outcomes.\n\nParticipants will receive either one of two real interventions or one of two sham (a procedure that looks like the real treatment but is not) interventions, involving either: 1. repetitive transcranial magnetic stimulation (rTMS)1; or 2. mindfulness-based real time fMRI neurofeedback (mb-rt-fMRI-NFB). Both procedures will measure brain capacity for change in CHR individuals, thus paving the way forward for future therapeutic interventions.\n\nThe main hypotheses to be addressed by this study are:\n\n1. \\- Following real interventions, novel biomarkers will be more effective predictors of clinical outcome than standard biomarkers in participants at CHR for psychosis\n2. \\- Following real interventions, novel biomarkers will be more effective predictors of clinical outcomes in participants who received the real intervention than in participants who received sham treatments\n3. \\- The novel interventions will reduce biomarker abnormalities in individuals with CHR relative to their own baselines and relative to healthy controls (HC)\n4. \\- The sham interventions will will not reduce biomarker abnormalities in individuals with CHR relative to their own baselines or relative to HC",[657,72],"Psychosis; Schizophrenia-Like",[659,660,661,662,663,664,665,666,667],"real-time fMRI neurofeedback (rt-fMRI-NFB)","mindfulness-based (mb)","mb rt-fMRI-NFB (mb-rt-fMRI-NFB)","repet. transcran mag stim (rTMS)","neuropsycho (NP)","diffusion tensor imaging (DTI)","clinical high risk (CHR)","healthy control (HC)","MATRICS Consenus Cog Batt (MCCB)","2025-04-16",{"date":670,"type":52},"2025-04-20",{"date":672,"type":52},"2024-01-01",{"date":674,"type":23},"2027-06-30",{"name":676,"class":59},"Beth Israel Deaconess Medical Center",{"id":678,"slug":679,"hasResults":12,"nctId":680,"briefTitle":681,"officialTitle":682,"acronym":4,"eligibilityCriteria":683,"healthyVolunteers":17,"sex":18,"minAge":97,"maxAge":4,"enrollmentInfo":684,"targetDuration":4,"studyType":24,"phases":685,"briefSummary":686,"conditions":687,"keywords":688,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":693,"lastUpdatePostDateStruct":694,"startDateStruct":696,"completionDateStruct":698,"leadSponsor":700,"locationsCount":90},"100572423","development-of-digital-services-for-parkinsons-disease-100572423","NCT06733077","Development of Digital Services for Parkinson's Disease","Development of Digital Diagnostics and Intervention Services for Parkinson's Disease","Inclusion criteria Participants with Parkinson's \\[Phase 1,2,3,4\\]\n\n* Diagnosis of idiopathic Parkinson's disease (UK Brain Bank Criteria) or other appropriate condition specific scale \\[stroke, multiple sclerosis, arthritis or osteoporosis\\]\n* Able to self-report history of daily gait freezing and\u002For festination for people with PD or gait and\u002For transfers affected by condition\n* Able to walk unsupported or using an aid for at least 5 minutes and satisfactory completion of the Canadian PARQ and if over 69 used to carrying out this level of exercise\n* Adult (+18 years old)\n* Normal or corrected-to-normal vision (Snellen Visual Acuity \\> 12\u002F18) or safe to mobilise with support\n* Montreal Cognitive assessment score \\>21 or ability to follow 2 stage commands\n\nHealthy participants \\[Phase 1,2,3\\]\n\n* With no long-term conditions affecting movement\n* Able to walk unsupported or using an aid for at least 3 minutes and satisfactory completion of the Canadian PARQ and if over 69 used to carrying out this level of exercise\n* Adult (+18 years old)\n* Normal or corrected-to-normal vision (Snellen Visual Acuity \\> 12\u002F18) or safe to mobilise with support\n* Montreal Cognitive assessment score \\>21 or ability to follow 2 stage commands\n\nExclusion criteria Participants with Parkinson's\n\n* Any physical or mental condition affecting ability to safely participate in this level of activity and capacity to understand testing as demonstrated by ability to safely follow commands and pass the PARQ by the research team.\n* Cognitive impairment affecting ability to safely participate and follow instructions\n* Any injury or disorder that may affect balance (other than Parkinson's or referring primary condition)\n* Any skin conditions or broken skin in the calf and behind knee area\n* Deep brain stimulation or pacemaker implants or other implant that may interfere with the measurement system\n* Medications likely to affect eye sight or use of virtual reality sytstem\n\nHealthy participants\n\n* Any physical or mental condition affecting ability to safely participate in this level of activity and capacity to understand testing as demonstrated by ability to safely follow commands and pass the PARQ by the research team.\n* Cognitive impairment affecting ability to safely participate and follow instructions\n* Any injury or disorder that may affect balance (other than Parkinson's or referring primary condition)\n* Any skin conditions or broken skin in the calf and behind knee area\n* Deep brain stimulation or pacemaker implants or other implants that may interfere with the measurement system",{"count":609,"type":23},[26],"In this project, ocular motor, pupil and gait data in people with Parkinson's disease (PD) will be collected in order to develop machine learning models for the diagnosis and monitoring of PD. With this, the investigators aim to advance the state of the art in PD diagnosis and monitoring. By integrating the principles of machine learning with high-quality sensor data, more accurate and earlier diagnosis could potentially be achieved. Ocular motor and pupil data will be collected with the standard clinical examination and with neos, a medical device approved for objective ocular motor and pupil measurement. Gait will be collected using an IMU sensor and GaitQ senti, a consumer device that allows for an objective and continuous remote gait monitoring.",[72,437],[689,690,691,692],"gaitQ","long-term movement condition","digital healthcare","MachineMD","2025-01-29",{"date":695,"type":52},"2025-02-03",{"date":697,"type":52},"2024-12-20",{"date":699,"type":23},"2026-04-01",{"name":701,"class":59},"University of Exeter"]